Literature DB >> 15780411

The interpretation of nucleic acid amplification tests for tuberculosis: do rapid tests change treatment decisions?

S J Conaty1, A P Claxton, D A Enoch, A C Hayward, M C I Lipman, S H Gillespie.   

Abstract

OBJECTIVES: To describe changes in treatment decisions after receipt of nucleic acid amplification (NAA) test for the diagnosis of M. tuberculosis.
METHODS: Retrospective notes review of treatment decisions in patients receiving a NAA test for suspected pulmonary or non-pulmonary tuberculosis at the Royal Free Hospital in London between March 2001 and February 2002. Notes were sought on a 50% random sample of patients with both smear and NAA negative specimens and all patients with other specimen results.
RESULTS: Two hundred and fifty patients were tested with NAA; clinical details were obtained on 138; 61 were ever treated. Seventeen (17/18) smear-negative patients were started on treatment after a positive NAA; none of six smear-negative patients treated prior to a negative NAA result had treatment stopped. Seventeen (17/21) smear-positive patients were treated prior to NAA result and all were NAA positive; treatment was delayed in four smear-positive patients until receipt of an NAA and one NAA-negative patient was not treated.
CONCLUSIONS: In routine practice a positive test in an untreated smear-negative patient leads to decision to treat in almost all, but the proportion testing positive is low (8% or 17/219). In patients already on treatment negative tests did not lead to decisions to stop.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15780411     DOI: 10.1016/j.jinf.2004.03.010

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  3 in total

1.  Impact of GeneXpert MTB/RIF assay on triage of respiratory isolation rooms for inpatients with presumed tuberculosis: a hypothetical trial.

Authors:  Lelia H Chaisson; Marguerite Roemer; David Cantu; Barbara Haller; Alexander J Millman; Adithya Cattamanchi; J Lucian Davis
Journal:  Clin Infect Dis       Date:  2014-08-04       Impact factor: 9.079

2.  Impact of GeneXpert MTB/RIF on patients and tuberculosis programs in a low-burden setting. a hypothetical trial.

Authors:  J Lucian Davis; L Masae Kawamura; Lelia H Chaisson; Jennifer Grinsdale; Jihane Benhammou; Christine Ho; Anna Babst; Houmpheng Banouvong; John Z Metcalfe; Mark Pandori; Philip C Hopewell; Adithya Cattamanchi
Journal:  Am J Respir Crit Care Med       Date:  2014-06-15       Impact factor: 21.405

3.  Amplified Mycobacterium tuberculosis direct test for diagnosing tuberculous pleurisy--a diagnostic accuracy study.

Authors:  Chieh-Mo Lin; Shu-Min Lin; Fu-Tsai Chung; Horng-Chyuan Lin; Kang-Yun Lee; Chien-Da Huang; Chih-Hsi Kuo; Chien-Ying Liu; Chun-Hua Wang; Han-Pin Kuo
Journal:  PLoS One       Date:  2012-09-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.